Search

Your search keyword '"Bergmann I"' showing total 409 results
Start Over Author "Bergmann I"
409 results on '"Bergmann I"'

9. Mittelohr I: Grundlagen, Klinik

Author

Wullstein, S. R., Hahn, P., Hoppe, F., Warmuth, M., Bernal-Sprekelsen, M., Weiß, S., Jergas, M., Bajanowski, Th., Ross, U. H., Laszig, R., Bornemann, H., Ulrich, Ch., Bergmann, I., Hartwein, J., Höing, R., Steuer, M. K., Herbst, H., Beuth, J., Pulverer, G., Matthias, R., Feldmann, Harald, and Herberhold, Claus

Published
1993
Full Text
View/download PDF

10. Macrophage migration inhibitory factor exerts pro-proliferative and anti-apoptotic effects via CD74 in murine hepatocellular carcinoma

Author

Wirtz, T, additional, Saal, A, additional, Bergmann, I, additional, Fischer, P, additional, Heinrichs, D, additional, Brandt, EF, additional, Koenen, MT, additional, Djudjaj, S, additional, Schneider, KM, additional, Boor, P, additional, Bucala, R, additional, Weiskirchen, R, additional, Bernhagen, J, additional, Trautwein, C, additional, and Berres, ML, additional

Published
2021
Full Text
View/download PDF

17. Die Crusoe-Trilogie als Utopie der Einsamkeit

Author

Bergmann, Ina, Klein, Dorothea, Bergmann, I ( Ina ), Klein, D ( Dorothea ), Karremann, Isabel, Bergmann, Ina, Klein, Dorothea, Bergmann, I ( Ina ), Klein, D ( Dorothea ), and Karremann, Isabel

Published
2020

32. Effect of allopurinol in addition to hypothermia treatment in neonates for hypoxic-ischemic brain injury on neurocognitive outcome (ALBINO): study protocol of a blinded randomized placebo-controlled parallel group multicenter trial for superiority (phase III)

Author

Benders, MJNL, Klebermass-Schrehof, K, Metsaranta, M, Rudiger, M, Poets, CF, Benders, M, Allegaert, K, Naulaers, G, Guimaraes, H, Stiris, T, Vanhatalo, S, Metsvaht, T, Engel, C, Maiwald, CA, von Oldershausen, G, Bergmann, I, Weiss, M, Wichera, CJBR, Eichhorn, A, Raubuch, M, Schuler, B, van Veldhuizen, CKW, Lameris, B, Jacobs, Y, van der Vlught-Meijer, R, Kliniken, T, Griesmaier, E, Salzburg, U, Brandner, J, Tackoen, M, Reibel, R, Cornette, L, Viellevoye, LR, Saik, P, Kaar, R, Andresson, P, Franz, AR, Carus, CG, Winkler, S, Hoehn, T, Teig, N, Schroth, M, Fusch, C, Thome, UH, Ehrhardt, H, Cattarossi, L, Mauro, I, Baraldi, E, Carnielli, V, Paterlini, MG, Napolitano, M, Faldini, F, Lista, GL, Barbarini, M, Pagani, L, Anna, S, Mastretta, E, Vento, G, Fumagalli, MM, Binotti, NM, van Weissenbruch, MM, van Straaten, HLM, Annink, KV, van Bel, F, Dudink, J, Derks, JB, de Boer, IP, Meijssen, CB, de Haan, TR, van Rooij, LG, van Hillegersberg, JL, van Dongen, M, Dassel, ACM, Dijkman, KP, van Houten, MA, van der Schoor, SRD, Nestaas, E, Mazela, J, Karpinski, L, Vilan, AI, de Pinho, LF, Ferraz, C, Pereira, A, Barroso, R, da Graca, M, Tome, T, Pinto, F, Vento, M, Rodilla, JM, Luz, M, Pico, C, Camprubi, MC, Suazo, JAH, Valverde, E, Lorenzo, JRF, Orgado, JM, Boix, H, Parrilla, FJ, Blanco, D, Moral-Pumarega, MT, Bassler, D, Maletzki, J, Knoepfli, C, Hagmann, C, Kleber, M, Schulzke, S, Stocker, M, Birkenmaier, A, Riedel, T, and ALBINO Study Grp

Subjects
Hypothermia therapy, Perinatal asphyxia, Allopurinol, Neonatal oxygen deficiency, Hypoxic-ischemic encephalopathy, Cerebral palsy, Childbirth outcome, Brain injury
Abstract

BackgroundPerinatal asphyxia and resulting hypoxic-ischemic encephalopathy is a major cause of death and long-term disability in term born neonates. Up to 20,000 infants each year are affected by HIE in Europe and even more in regions with lower level of perinatal care. The only established therapy to improve outcome in these infants is therapeutic hypothermia. Allopurinol is a xanthine oxidase inhibitor that reduces the production of oxygen radicals as superoxide, which contributes to secondary energy failure and apoptosis in neurons and glial cells after reperfusion of hypoxic brain tissue and may further improve outcome if administered in addition to therapeutic hypothermia.MethodsThis study on the effects of ALlopurinol in addition to hypothermia treatment for hypoxic-ischemic Brain Injury on Neurocognitive Outcome (ALBINO), is a European double-blinded randomized placebo-controlled parallel group multicenter trial (Phase III) to evaluate the effect of postnatal allopurinol administered in addition to standard of care (including therapeutic hypothermia if indicated) on the incidence of death and severe neurodevelopmental impairment at 24months of age in newborns with perinatal hypoxic-ischemic insult and signs of potentially evolving encephalopathy. Allopurinol or placebo will be given in addition to therapeutic hypothermia (where indicated) to infants with a gestational age36weeks and a birth weight2500g, with severe perinatal asphyxia and potentially evolving encephalopathy. The primary endpoint of this study will be death or severe neurodevelopmental impairment versus survival without severe neurodevelopmental impairment at the age of two years. Effects on brain injury by magnetic resonance imaging and cerebral ultrasound, electric brain activity, concentrations of peroxidation products and S100B, will also be studied along with effects on heart function and pharmacokinetics of allopurinol after iv-infusion.DiscussionThis trial will provide data to assess the efficacy and safety of early postnatal allopurinol in term infants with evolving hypoxic-ischemic encephalopathy. If proven efficacious and safe, allopurinol could become part of a neuroprotective pharmacological treatment strategy in addition to therapeutic hypothermia in children with perinatal asphyxia.Trial registrationNCT03162653, www.ClinicalTrials.gov, May 22, 2017.

Published
2019

35. Effect of allopurinol in addition to hypothermia treatment in neonates for hypoxic-ischemic brain injury on neurocognitive outcome (ALBINO): Study protocol of a blinded randomized placebo-controlled parallel group multicenter trial for superiority (phase III)

Author

Maiwald, C. A., Annink, K. V., Rudiger, M., Benders, M. J. N. L., Van Bel, F., Allegaert, K., Naulaers, G., Bassler, D., Klebermass-Schrehof, K., Vento, M., Guimaraes, H., Stiris, T., Cattarossi, L., Metsaranta, M., Vanhatalo, S., Mazela, J., Metsvaht, T., Jacobs, Y., Franz, A. R., Poets, C. F., Van Veldhuizen, C., Engel, C., Von Oldershausen, G., Bergmann, I., Weiss, M., Wichera, C. J. B. R., Eichhorn, A., Raubuch, M., Schuler, B., Van Veldhuizen, C. K. W., Lameris, B., Van Der Vlught-Meijer, R., Griesmaier, E., Brandner, J., Tackoen, M., Reibel, R., Lecart, C., Cornette, L., Malfilatre, G., Viellevoye, R., Ilmoja, M. -L., Saik, P., Kaar, R., Andresson, P., Schloesser, R., Ott, T., Winkler, S., Hoehn, T., Teig, N., Schroth, M., Thome, U. H., Ehrhardt, H., Mauro, I., Baraldi, E., Carnielli, V., Paterlini, G., Napolitano, M., Faldini, P. F., Lista, G., Visintin, G., Barbarini, M., Pagani, L., Mastretta, E., Vento, Giovanni, Fumagalli, M., Binotti, M., Van Weissenbruch, M. M., Van Straaten, H. L. M., Dudink, J., Derks, J. B., De Boer, I. P., Meijssen, C. B., De Haan, T. R., Van Rooij, L. G., Van Hillegersberg, J. L., Van Dongen, M., Bruinenberg, J., Dijkman, K. P., Van Houten, M. A., Van Der Schoor, S. R. D., Salvesen, B., Schneider, M., Nestaas, E., Nakstad, B., Karpinski, L., Gulczynska, E., Krolak-Olejnik, B., Bokiniec, R., Vilan, A. I., De Pinho, L. F., Ferraz, C., Pereira, A., Barroso, R., Da Graca, A. M., Tome, T., Pinto, F., Rodilla, J. M., Lubian, S., Camprubi, M. C., Suazo, J. A. H., Valverde, E., Lorenzo, J. R. F., Orgado, J. M., Boix, H., Parrilla, F. J., Moral-Pumarega, M. T., Maletzki, J., Knoepfli, C., Hagmann, C., Schulzke, S., Stocker, M., Birkenmaier, A., Riedel, T., Ehni, H. -J., Janvier, A., Marckmann, G., Vento G. (ORCID:0000-0002-8132-5127), Maiwald, C. A., Annink, K. V., Rudiger, M., Benders, M. J. N. L., Van Bel, F., Allegaert, K., Naulaers, G., Bassler, D., Klebermass-Schrehof, K., Vento, M., Guimaraes, H., Stiris, T., Cattarossi, L., Metsaranta, M., Vanhatalo, S., Mazela, J., Metsvaht, T., Jacobs, Y., Franz, A. R., Poets, C. F., Van Veldhuizen, C., Engel, C., Von Oldershausen, G., Bergmann, I., Weiss, M., Wichera, C. J. B. R., Eichhorn, A., Raubuch, M., Schuler, B., Van Veldhuizen, C. K. W., Lameris, B., Van Der Vlught-Meijer, R., Griesmaier, E., Brandner, J., Tackoen, M., Reibel, R., Lecart, C., Cornette, L., Malfilatre, G., Viellevoye, R., Ilmoja, M. -L., Saik, P., Kaar, R., Andresson, P., Schloesser, R., Ott, T., Winkler, S., Hoehn, T., Teig, N., Schroth, M., Thome, U. H., Ehrhardt, H., Mauro, I., Baraldi, E., Carnielli, V., Paterlini, G., Napolitano, M., Faldini, P. F., Lista, G., Visintin, G., Barbarini, M., Pagani, L., Mastretta, E., Vento, Giovanni, Fumagalli, M., Binotti, M., Van Weissenbruch, M. M., Van Straaten, H. L. M., Dudink, J., Derks, J. B., De Boer, I. P., Meijssen, C. B., De Haan, T. R., Van Rooij, L. G., Van Hillegersberg, J. L., Van Dongen, M., Bruinenberg, J., Dijkman, K. P., Van Houten, M. A., Van Der Schoor, S. R. D., Salvesen, B., Schneider, M., Nestaas, E., Nakstad, B., Karpinski, L., Gulczynska, E., Krolak-Olejnik, B., Bokiniec, R., Vilan, A. I., De Pinho, L. F., Ferraz, C., Pereira, A., Barroso, R., Da Graca, A. M., Tome, T., Pinto, F., Rodilla, J. M., Lubian, S., Camprubi, M. C., Suazo, J. A. H., Valverde, E., Lorenzo, J. R. F., Orgado, J. M., Boix, H., Parrilla, F. J., Moral-Pumarega, M. T., Maletzki, J., Knoepfli, C., Hagmann, C., Schulzke, S., Stocker, M., Birkenmaier, A., Riedel, T., Ehni, H. -J., Janvier, A., Marckmann, G., and Vento G. (ORCID:0000-0002-8132-5127)

Abstract

Background: Perinatal asphyxia and resulting hypoxic-ischemic encephalopathy is a major cause of death and long-term disability in term born neonates. Up to 20,000 infants each year are affected by HIE in Europe and even more in regions with lower level of perinatal care. The only established therapy to improve outcome in these infants is therapeutic hypothermia. Allopurinol is a xanthine oxidase inhibitor that reduces the production of oxygen radicals as superoxide, which contributes to secondary energy failure and apoptosis in neurons and glial cells after reperfusion of hypoxic brain tissue and may further improve outcome if administered in addition to therapeutic hypothermia. Methods: This study on the effects of ALlopurinol in addition to hypothermia treatment for hypoxic-ischemic Brain Injury on Neurocognitive Outcome (ALBINO), is a European double-blinded randomized placebo-controlled parallel group multicenter trial (Phase III) to evaluate the effect of postnatal allopurinol administered in addition to standard of care (including therapeutic hypothermia if indicated) on the incidence of death and severe neurodevelopmental impairment at 24 months of age in newborns with perinatal hypoxic-ischemic insult and signs of potentially evolving encephalopathy. Allopurinol or placebo will be given in addition to therapeutic hypothermia (where indicated) to infants with a gestational age ≥ 36 weeks and a birth weight ≥ 2500 g, with severe perinatal asphyxia and potentially evolving encephalopathy. The primary endpoint of this study will be death or severe neurodevelopmental impairment versus survival without severe neurodevelopmental impairment at the age of two years. Effects on brain injury by magnetic resonance imaging and cerebral ultrasound, electric brain activity, concentrations of peroxidation products and S100B, will also be studied along with effects on heart function and pharmacokinetics of allopurinol after iv-infusion. Discussion: This trial will provide d

Published
2019

41. New fossils from Jebel Irhoud, Morocco and the pan-African origin of Homo sapiens

Author

Hublin, J.J., Ben-Ncer, A., Bailey, S.E., Freidline, S.E., Neubauer, S., Skinner, M.M., Bergmann, I., Le Cabec, A., Benazzi, S., Harvati, K., Gunz, P., Hublin J.J., Department of Human Evolution [Leipzig], Max Planck Institute for Evolutionary Anthropology [Leipzig], Max-Planck-Gesellschaft-Max-Planck-Gesellschaft, Chaire internationale Paléoanthropologie, Collège de France (CdF (institution)), Institut National des Sciences de l'Archéologie et du Patrimoine [INSAP] - Rabat, Center for the study of Human Origins, New York University [New York] (NYU), NYU System (NYU)-NYU System (NYU), University of Kent [Canterbury], Alma Mater Studiorum Università di Bologna [Bologna] (UNIBO), University of Tübingen, Max Planck Society, Hublin J.J., Hublin, Jean-Jacque, Ben-Ncer, Abdelouahed, Bailey, Shara E., Freidline, Sarah E., Neubauer, Simon, Skinner, Matthew M., Bergmann, Inga, Le Cabec, Adeline, Benazzi, Stefano, Harvati, Katerina, and Gunz, Philipp

Subjects
0301 basic medicine, 010506 paleontology, [SHS.ARCHEO]Humanities and Social Sciences/Archaeology and Prehistory, Hominidae, [SHS.ANTHRO-BIO]Humanities and Social Sciences/Biological anthropology, Morphology (biology), Mandible, 01 natural sciences, 03 medical and health sciences, Paleontology, Phylogenetics, Animals, Humans, Clade, Middle Stone Age, Phylogeny, 0105 earth and related environmental sciences, Multidisciplinary, biology, Thermoluminescence dating, Animal, Fossils, [SDV.BID.EVO]Life Sciences [q-bio]/Biodiversity/Populations and Evolution [q-bio.PE], Skull, Fossil, biology.organism_classification, Morocco, 030104 developmental biology, Homo sapiens, Evolutionary biology, Chronology as Topic, Face, Africa, Human taxonomy, Tooth, Human
Abstract

Fossil evidence points to an African origin of Homo sapiens from a group called either H. heidelbergensis or H. rhodesiensis. However, the exact place and time of emergence of H. sapiens remain obscure because the fossil record is scarce and the chronological age of many key specimens remains uncertain. In particular, it is unclear whether the present day ‘modern’ morphology rapidly emerged approximately 200 thousand years ago (ka) among earlier representatives of H. sapiens1 or evolved gradually over the last 400 thousand years2. Here we report newly discovered human fossils from Jebel Irhoud, Morocco, and interpret the affinities of the hominins from this site with other archaic and recent human groups. We identified a mosaic of features including facial, mandibular and dental morphology that aligns the Jebel Irhoud material with early or recent anatomically modern humans and more primitive neurocranial and endocranial morphology. In combination with an age of 315 ± 34 thousand years (as determined by thermoluminescence dating)3, this evidence makes Jebel Irhoud the oldest and richest African Middle Stone Age hominin site that documents early stages of the H. sapiens clade in which key features of modern morphology were established. Furthermore, it shows that the evolutionary processes behind the emergence of H. sapiens involved the whole African continent.

Published
2017

42. Polyphasic analyses of methanogenic archaeal communities in agricultural biogas plants

Author

Nettmann, E., Bergmann, I., Pramschufer, S., Mundt, K., Plogsties, V., Herrmann, C., and Klocke, M.

Subjects
Archaeabacteria -- Physiological aspects, Archaeabacteria -- Environmental aspects, Biogas -- Protection and preservation, Methane -- Environmental aspects, Methanobacteriaceae -- Physiological aspects, Methanobacteriaceae -- Environmental aspects, Biological sciences
Abstract

A polyphasic approach with three different culture-independent techniques were applied to gain insight into the diversity of methane-producing Archaea in six full-scale biogas plants supplied with renewable raw material and different types of liquid manure as substrates. The results revealed hydrogenotrophic methanogenesis as a predominant pathway for methane synthesis in five of the six analyzed biogas plants and also pointed to the correlation between the absence of Methanosaetaceae in the biogas reactors and the observed high concentrations of total ammonia.

Published
2010

43. Functional nanomaterials for electric power industry

Author

FRECHETTE, M., VAUGHAN, A., ALLAIS, A., HÄRING, U., ANDRITSCH, T., BERGMANN, I., CASTELLON, J., CRISTIANO, A., DAVID, E., DARQUES, M., ENGLUND, V., FABIANI, D., GERMANO, A., HAN, S. J., PERROT, F., QUIRKE, N., REED, C., SHIMIZU, T., SUTTON, S., TANAKA, T., WEIDNER, J., Institut de Recherche d'Hydro-Québec [Varennes] (IREQ), Delft University of Technology (TU Delft), Institut d’Electronique et des Systèmes (IES), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Groupe énergie et matériaux (GEM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), University of Bologna, Centre d'Etudes Nucléaires de Bordeaux Gradignan (CENBG), Université Sciences et Technologies - Bordeaux 1-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Centre de Physique des Particules de Marseille (CPPM), Aix Marseille Université (AMU)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Advanced Photon Source [ANL] (APS), Argonne National Laboratory [Lemont] (ANL)-University of Chicago-US Department of Energy, Cigre Technical Brochure 661, Working Group D1.40, University of Bologna/Università di Bologna, and Université Sciences et Technologies - Bordeaux 1 (UB)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)

Subjects
ComputingMilieux_MISCELLANEOUS, [SPI.TRON]Engineering Sciences [physics]/Electronics
Abstract

International audience

Published
2016

44. Cubic versus spherical magnetic nanoparticles: the role of surface anisotropy

Author

Salazar-Alvarez, G., Qin, J., Sepelak, V., Bergmann, I., Vasilakaki, M., Trohidou, K.N., Ardisson, J.D., Macedo, W.A.A., Mikhaylova, M., Muhammed, M., Baro, M.D., and Nogues, J.

Subjects
Anisotropy -- Analysis, Iron compounds -- Magnetic properties, Iron compounds -- Structure, Nanoparticles -- Structure, Nanoparticles -- Magnetic properties, Chemistry
Abstract

Experimental and theoretical studies were conducted to understand the magnetic properties of maghemite ([gamma]-[Fe.sub.2][O.sub.3]) cubic and spherical nanoparticles of similar sizes. The results obtained provide insight into the different random surface anisotropy of the two morphologies combined with the low magnetocrystalline anisotropy of [gamma]-[Fe.sub.2][O.sub.3] which is the origin of these effects.

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results